PPAR-γ agonists, mainly 15d-PGJ2, reduce eosinophil recruitment following allergen challenge  by Farnesi-de-Assunção, Thais S. et al.
Cellular Immunology 273 (2012) 23–29Contents lists available at SciVerse ScienceDirect
Cellular Immunology
journal homepage: www.elsevier .com/locate /yc immPPAR-c agonists, mainly 15d-PGJ2, reduce eosinophil recruitment following
allergen challenge
Thais S. Farnesi-de-Assunção a,b, Claudiney F. Alves b, Vanessa Carregaro c, Jhony R. de Oliveira b,
Carlos A.T. da Silva a,b, Alessandra B. Cheraim b, Fernando Q. Cunha d, Marcelo H. Napimoga b,e,⇑
a Laboratory of Immunology, Federal University of Triangulo Mineiro, Uberaba, MG, Brazil
b Laboratory of Biopathology and Molecular Biology, University of Uberaba, Uberaba, MG, Brazil
cDepartment of Immunology, Faculty of Medicine of Ribeirão Preto, University of São Paulo, Ribeirão Preto, SP, Brazil
dDepartment of Pharmacology, Faculty of Medicine of Ribeirão Preto, University of São Paulo, Ribeirão Preto, SP, Brazil
e Laboratory of Immunology and Molecular Biology, São Leopoldo Mandic Institute and Research Center, Campinas, SP, Brazil
a r t i c l e i n f oArticle history:
Received 19 August 2011
Accepted 29 November 2011





Inﬂammation0008-8749  2011 Elsevier Inc. Open access under the El
doi:10.1016/j.cellimm.2011.11.010
⇑ Corresponding author. Address: Laboratory of
Biology, São Leopoldo Mandic Institute and Rese
Junqueira, 13 Campinas, SP, CEP. 13045-755, Brazil. F
E-mail addresses: napimogamh@yahoo.com, m
(M.H. Napimoga).a b s t r a c t
We evaluate the immunomodulation of Peroxisome proliferator-activated receptor-c (PPAR-c) agonists
15d-PGJ2 and rosiglitazone (RGZ) in a model of chronic eosinophilia. 15d-PGJ2 and RGZ signiﬁcantly
reduce eosinophil migration into the peritoneal cavity and down-regulate the eosinopoiesis. The synthe-
sis of IL-5 was decreased after the treatment with 15d-PGJ2 and RGZ corroborating with the eosinophil
migration inhibition. However, IgE was decreased only after the administration of 15d-PGJ2 in part due
to B-cell inhibition. We also observed a decrease in the synthesis of IL-33, IL-17 and IL-23, suggesting that
besides the modulation of Th2 pattern, there is a modulation via IL-23 and IL-17 suggesting a role of these
cytokines in the eosinophil recruitment. In fact IL-17/ mice failed to develop an eosinophilic response.
Altogether, the results showed that PPAR-c agonists mainly 15d-PGJ2, have therapeutic efﬁcacy in eosin-
ophil-induced diseases with an alternative mechanism of control, via IL-23/IL-17 and IL-33.
 2011 Elsevier Inc. Open access under the Elsevier OA license.1. Introduction
Peroxisome proliferator-activated receptor-c (PPAR-c) is a
member of the nuclear hormone receptor superfamily of ligand-
activated transcription factors. Both natural and synthetic ligands
have been reported for PPAR-c. Naturally occurring compounds
that have been reported to bind PPAR-c include a number of fatty
acids and eicosanoid derivatives such as 9- or 13-hydroxyoctadie-
noic acid and prostaglandin derivative 15-deoxy-D12,14-prostaglan-
din J2 (15d-PGJ2) [1]. Prostanoids play a critical role in inﬂammation
and for many years, cyclooxygenases (COX) enzymes and their
products have been considered mainly pro-inﬂammatory agents
[2], however, it has been proposed a role of COX-2 in inﬂammatory
resolution. A late peak of PGD2 production and its product, the
15d-PGJ2 were observed together with an exacerbating effect of
NSAIDs at late stages of the inﬂammatory response [3]. Besides,
the most widely used synthetic agonists of PPAR-c are members
of a class of antidiabetic agents known as thiazolidinediones (TZDs),
including rosiglitazone, troglitazone, and pioglitazone.sevier OA license. 
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fects of the PPAR-c agonists in different animal models [4–9] as
well as its potential useful to control eosinophil-mediated inﬂam-
matory diseases [10,11], since it was demonstrated that eosino-
phils express PPAR-c and the stimulation with a synthetic
agonist for PPAR-c attenuated the factor-induced eosinophil sur-
vival and chemotaxis [12,13]. Besides, administration of PPAR-c
agonists had beneﬁcial effects on pathological conditions, includ-
ing airway hyper-responsiveness and lung eosinophilia in a murine
model of asthma [14] as well as negatively regulates allergic rhini-
tis in mice [15]. Also, eosinophils cultured with therapeutic con-
centrations of theophylline and dexamethasone markedly
enhanced both mRNA and protein levels of PPAR-c, suggesting that
the increase in PPAR-c expression on eosinophils may play a role in
the anti-inﬂammatory effects of both drugs.
The initial event in an asthma-like disease is the interaction be-
tween dendritic cells (DC) and T cells, leading to the generation of
Th2 cells including IL-5 an important cytokine to induce the eosin-
ophil recruitment [16]. Another Th2-related cytokine is the IL-33,
which can act directly on Th2 cells increasing the secretion of
Th2 cytokines such as IL-5 and IL-13 [17], as well as can also act
as a chemo-attractant for Th2 cells [18]. Asthma-like disease has
long been characterized as a Th2-based immune response,
however, studies suggest that this disease is a heterogeneous
disorder with distinct types of inﬂammatory processes, including
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amplify the Th17 cells, has been demonstrated to be an important
immunoregulatory factor during experimental asthma. Indeed, ex-
cess generation of IL-23 [20] or transgenic over-expression of IL-23
receptor [21] can exacerbate allergen-induced inﬂammation
through increased Th2-cell and eosinophil activity and/or
recruitment.
It is noteworthy that the PPAR-c agonists, bind to the PPAR-c/
RXR heterodimer that competes for recruitment of the co-activa-
tors CREB binding protein (CBP) and p-300 [1]. The limited avail-
ability of these co-activators inhibits the activation of the
transcription factors activator protein-1 (AP-1), NF-jB, and conse-
quently inhibits pro-inﬂammatory gene expression. However, 15d-
PGJ2 may also exert PPAR-c-independent anti-inﬂammatory ef-
fects through direct modiﬁcation of cysteine residues of the inhib-
itor-KB kinase and NF-jB subunits, and direct inhibition of the
extracellular regulated kinase (ERK1/2) [22]. Thus, the use of
15d-PGJ2 as a pharmacological tool may be more effective than
the use of other PPAR-c agonists. Besides, there are few data
regarding the use of natural agonist 15d-PGJ2 as a therapeutic drug
choice to control eosinoﬁlic inﬂammation.
Therefore, in the present study, we used a model of chronic
eosinophilic inﬂammation induced in mice by subcutaneous egg
white implants (EWI) to evaluate the immunomodulatory effect
of the PPAR-c agonists. This model involves surgical implantation
of a piece of heat-coagulated hen egg white, which is followed by
chronic, intense eosinophilic inﬂammation at the implant site,
accompanied by a large increase in bone-marrow eosinophilopoie-
sis lasting several weeks [23].2. Material and methods
2.1. Animals
Male C57BL/6 wild-type and IL-17 deﬁcient (IL-17/) mice
weighing 20–25 g were obtained from the Faculty of Medicine of
Ribeirão Preto (University of São Paulo, São Paulo, Brazil). The ani-
mals were kept in appropriate cages in a temperature-controlled
room, with a 12 h dark/light cycle. Free access to water and food
was provided, and an acclimatization period of about 7 days in
the laboratory was used prior to the experiment. All animals were
manipulated in accordance with the Guiding Principles in The Care
and Use of Animals, approved by the Council of the American Phys-
iologic Society. This animal study was deemed to be ethical accord-
ing to the Brazilian Guidelines (Resolution 11794/2008) and was
approved by the Animal Ethics Committee of the University of
Uberaba (# 049/2009).Fig. 1. Time course of eosinophil migration following challenge with OVA. Mice
submitted or not (Sham) to a subcutaneous implant of heat-coagulated egg white
(EWI) were challenged with OVA (10 lg/cavity) 15 days thereafter. The eosinophils
migration was determined in the peritoneal exudates 24, 48 and 72 h after
challenge. Data are the mean ± SD and are representative of 6 mice/group. #P < 0.05
compared to 24 and 72 h EWI-challenged. ⁄P < 0.01 compared with Sham controls.2.2. Egg white implant
Dehydrated hen egg white was prepared as previously de-
scribed [23], by dissolving it in distilled water, to a 100 g/l ﬁnal
concentration, and dispensing 45 ll per well in a 96-well plate
(4.5 mg/well). Heat coagulation was carried out on the plate in a
microwave oven (90 s at 900 Hz). Pellets were recovered and dehy-
drated in absolute ethanol for 48 h. The dehydrated pellets were al-
lowed to dry at room temperature for 24 h and stored at room
temperature until use. Mice were anaesthesiated with tribromo-
ethanol (250 mg/kg, i.p.) and a dorsal incision was made after local
trichotomy. Rehydrated egg white pellets were implanted subcuta-
neously through the dorsal incision, and the skin was sutured. Con-
trol (sham-implanted) mice were submitted to the surgery, but
received no implant. After 15 days from surgery, different groups
of animals were challenged with ovalbumin (10 lg; OVA) or PBS
(phosphate buffer solution, pH 7.2) by intraperitoneal injection.Animals were euthanized at 0, 24, 48 or 72 h after the challenge
with ovalbumin. The current conditions used (challenge with
10 lg per cavity and 15 days after implant perform the challenge
with ovalbumin), was chosen based on a previous study [23].2.3. Drugs and treatments
To evaluate the effect of 15d-PGJ2 (100, 300 or 1000 lg/kg; Sig-
ma–Aldrich, USA) or rosiglitazone (1, 3 or 10 mg/kg, RGZ; Avan-
dia, Glaxo-SmithKline, USA) on eosinophil recruitment, mice
were injected with the indicated doses of each drug 30 min before
challenge and every 12 h (for 15d-PGJ2) or after 24 h (for RGZ) of
intraperitoneal challenge with OVA. Cell migration was evaluated
48 h after challenge (based on the time course curve, Fig. 1). 15d-
PGJ2 was dissolved in sterile PBS and injected subcutaneously
(s.c.) in a ﬁnal volume of 0.2 ml as previously described [5]. RGZ
was dissolved in sterile PBS and administered by oral gavage in a
ﬁnal volume of 0.2 ml as previously described [8].2.4. Blood sample collection and IgE quantiﬁcation
At 48 h after the challenge, blood was drawn by puncturing the
orbital plexus and centrifuged. Serum was frozen and stored at
70 C for IgE measurements by ELISA using protocols supplied
by the manufacturer (BD Biosciences). After all standard proce-
dures, the optical density (O.D.) was measured at 450 nm. Results
were expressed as pg/mL based on the standard curves.2.5. Leukocyte and eosinophil counts from peritoneal lavage or bone-
marrow
Forty-eight hours after challenge, the mice were euthanized,
and the peritoneal cavity washed for 3 min with 3 mL of PBS con-
taining 1 mM EDTA, and the solution was recovered. Also, bone-
marrow cells were obtained by ﬂushing the two femurs of mice
with RPMI-1640 medium (LGC Biotechnology, São Paulo, Brazil)
containing 10% fetal calf serum (Invitrogen) and penicillin/strepto-
mycin (Invitrogen). Total counts were performed in a Newbauer
chamber and the frequency of cells stained for eosinophil peroxi-
dase (EPO) was determined in cytocentrifuge (Cientec, Piracicaba,
SP, Brazil) smears of freshly harvested peritoneal lavage or bone-
marrow cells. Data are reported as means ± standard deviations
of the number of eosinophils per cavity, and each count was carried
out at least twice, with differences of less than 10%.
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The IL-5, IL-17, IL-23 and IL-33 levels in the peritoneal exudates
from OVA-challenged mice were detected by ELISA using protocols
supplied by the manufacturer (R&D Systems, Minneapolis, USA).
After all standard procedures, the optical density (O.D.) was mea-
sured at 490 nm. Results are expressed as pg/mL of each cytokine,
based on the standard curves.Fig. 2. 15d-PGJ2 decrease the eosinophil migration and the eosinopoiesis. Mice
submitted or not (Sham) to a subcutaneous implant of heat-coagulated egg white2.7. B cell proliferation
To assess the inﬂuence of 15d-PGJ2 treatment in B cell prolifer-
ation, the spleens from naïve mice were harvested and washed
twice with PBS separately. Tissues were minced and the cells were
ﬁltered through a cell strainer and centrifuged at 500g at 4 C for
10 min. The cell pellet was re-suspended in RPMI-1640 medium
(LGC Biotechnology) to a concentration of 2.5  106 cells/ml and
it was added in 24-well microtitre plates. Plated cells were treated
with 15d-PGJ2 (5.0 lM) or vehicle for 1 h and, then, stimulated
with LPS (2400 ng/ml) or medium for 24 h. Afterwards, samples
obtained from above mentioned culture were suspended and incu-
bated for 30 min at 4 C in PBS containing 2% of bovine serum albu-
min (PBS-S) and FccIR block mAb (CD16/CD32) to avoid
nonspeciﬁc background staining. After the blocking step, B cells
were identiﬁed by characteristic size (FSC) and granulosity (SSC)
combined with two-color analysis. Brieﬂy, the lymphocytes were
identiﬁed as CD19+ using speciﬁc antibody conjugate with PE (BD
Biosciences PharMingen, San Diego, CA, USA). The isotype controls
used were rat IgG2b (BD Biosciences PharMingen). After staining,
cells were ﬁxed with 1% paraformaldehyde and analyzed by ﬂow
cytometry (FACScan™ and CELLQuest™ software; BD Biosciences
PharMingen).(EWI) were challenged with OVA (10 lg/cavity) or PBS. EWI groups were treated,
30 min before ovalbumin challenge, with 15d-PGJ2 (100, 300 or 1000 lg/kg) each
12 h. The eosinophils were harvested from the peritoneal cavity (A) or bone-
marrow (B) from OVA-challenged mice treated with different doses of 15d-PGJ2
48 h after challenge. #P < 0.05 compared with control groups. ⁄P < 0.05 compared
with OVA-challenge mice without treatment. Data are the mean ± SD and are
representative of 6 mice/group.2.8. Statistical analysis
The means from different treatments were compared using AN-
OVA. When statistically signiﬁcant differences were identiﬁed,
individual comparisons were subsequently made using Bonferron-
i’s t-test for unpaired values. Statistical signiﬁcance was set at
P < 0.05.3. Results
We ﬁrst carried out an experiment to evaluate the time course
of eosinophil migration following challenge with the standardized
dose (10 lg/cavity) of OVA. As shown in Fig. 1, signiﬁcantly in-
creased eosinophil numbers were observed in the peritoneal cavity
of EWI mice, relative to Sham controls 24, 48 and 72 h after chal-
lenge (p < 0.01 in all cases). Moreover, at 48 h after the challenge
in the EWI mice, an increased eosinophil migration was observed,
statistically signiﬁcant in comparison to 24 and 72 h (p < 0.05),
demonstrating that at 48 h the eosinophil migration to the perito-
neal cavity reached the peak. Therefore, the time point of 48 h was
chosen as the observation time for the subsequent experiments.
To evaluate the pharmacological potential of PPAR-c agonists to
inhibit eosinophil migration induced by ovalbumin, EWI mice were
treated, before ovalbumin challenge, with 15d-PGJ2 (100, 300 and
1000 lg/kg) or rosiglitazone (1, 3 and 10 mg/kg). As demonstrated
in the Fig. 2A, the shammice challenge with PBS or OVA did not in-
duce an eosinophilic recruitment to the peritoneal cavity. The same
pattern was observed in the PBS-challenge EWI mice. All three
groups were used as control. On the other hand, the OVA-challenge
EWI mice had a statistical increase (p < 0.05) in the eosinophil
migration at 48 h.The treatment with the natural PPAR-c agonist 15d-PGJ2 100,
300 or 1000 lg/kg decreased in a dose-dependent manner
(p < 0.05) the eosinophil migration to the peritoneal cavity in mice,
induced by intraperitoneal injection of OVA determined 48 h later.
Moreover, we also evaluate the effect of 15d-PGJ2 in bone-marrow
eosinopoiesis in EWI recipients, as well as sham-implanted mice.
OVA-challenge EWI mice had a statistical increase (p < 0.05) in
the eosinopoiesis at 48 h, and only the dose of 1000 lg/kg of
15d-PGJ2 statistically decrease the eosinopoiesis on bone-marrow
(p < 0.05) as demonstrated in Fig. 2B.
We further analyzed the potential role of the synthetic PPAR-c
agonist RGZ to inhibit eosinophil migration to the peritoneal cav-
ity. As demonstrated in the Fig. 3A, OVA-challenge EWI mice had
a statistical increase (p < 0.05) in the eosinophil migration to the
peritoneal cavity at 48 h. The oral administration of RGZ 1, 3 and
10 mg/kg statistically decreased the eosinophil migration
(p < 0.05). We did not observe a dose-dependent pattern, although
the dose of 10 mg/kg demonstrated a slight better efﬁcacy. Regard-
ing the effect of RGZ on bone-marrow eosinopoiesis in EWI recip-
ients we demonstrated that both doses of 3 and 10 mg/kg did
statistically (p < 0.05) reduce the eosinopoiesis (Fig. 3B).
Next, we analyzed the pattern of some cytokines in the OVA-
sensitize mice treated with both PPAR-c agonists. IL-5 (Fig. 4A)
and IL-33 (Fig. 4B) levels in the OVA-challenge EWI mice was sta-
tistically higher (p < 0.05) than Sham mice. Both RGZ and 15d-PGJ2
inhibited the release of IL-5 and IL-33 in a dose-dependent fashion,
Fig. 3. Rosiglitazone (RGZ) decrease the eosinophil migration and the eosinopoiesis.
Mice submitted or not (Sham) to a subcutaneous implant of heat-coagulated egg
white (EWI) were challenged with OVA (10 lg/cavity) or PBS. EWI groups were
treated, 30 min before ovalbumin challenge, with rosiglitazone (RGZ) (1, 3 or
10 mg/kg) every 24 h. The eosinophils were harvested from the peritoneal cavity (A)
or bone-marrow (B) from OVA-challenged mice treated with different doses of RGZ
48 h after challenge. #P < 0.05 compared with control groups. ⁄P < 0.05 compared
with OVA-challenge mice without treatment. Data are the mean ± SD and are
representative of 6 mice/group.
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1000 lg/kg of 15d-PGJ2 for both cytokines. Furthermore, IL-17
(Fig. 4C) and IL-23 (Fig. 4D) levels in the OVA-challenge EWI mice
was statistically increased (p < 0.05) than Sham mice. Both RGZ
and 15d-PGJ2 inhibited the release of IL-17 in a dose-dependent
fashion, but the statistical signiﬁcant doses were 3 and 10 mg/kg
of RGZ and 300 and 1000 lg/kg of 15d-PGJ2 (Fig. 4C). Regarding
the IL-23 the doses of 3 and 10 mg/kg of RGZ and 1000 lg/kg of
15d-PGJ2 showed statistical signiﬁcant decrease (Fig. 4D).
To conﬁrm the importance of the IL-17 in the recruitment of
eosinophils, we used a set of C57/B6 IL-17/ mice. As observed
in the Fig. 5A, the EWI-challenge mice had a signiﬁcant increase
in the eosinohpil inﬂux in contrast to EWI-PBS challenge
(p < 0.05). Interestingly, the EWI-challenge IL-17/ mice did not
show an intense eosinophil migration after the OVA-challenge
being the same as PBS-challenge mice (Fig. 5A, white bars). The
same pattern was observed in the eosinopoiesis by analyzing the
number of eosinophis from the bone-marrow (Fig. 5B).
Serum levels of IgE in the OVA-challenge EWI mice group were
signiﬁcantly higher than that in the control groups. Interestingly,
the administration of RGZ (all doses tested) did not statistically re-
duce the serum levels of IgE (Fig. 6A). However, at the dose of
1000 lg/kg of 15d-PGJ2 it was observed a statistical decrease
(p < 0.05) in the levels of IgE (Fig. 6A). Next, we tested the effect
of the 15d-PGJ2 in an in vitro B cell proliferation in the presenceof LPS. As demonstrated in Fig. 6B, it was possible to observe a sig-
niﬁcant inhibition of the B cell proliferation when incubated with
5 lM of 15d-PGJ2.4. Discussion
In the present study we partially elucidated the mechanism
underlying the role of PPAR-c agonists-mediated suppression of
eosinophils recruitment toward inﬂammatory stimuli using a
mouse asthma-like model, in which eosinophils recruitment is a
key event. Furthermore, we also showed that this decreased eosin-
ophil recruitment is associated with PPAR-c agonists-mediated
suppression of several cytokines including the cytokines that acts
selectively on the eosinophil lineage, promoting eosinopoiesis,
migration, activation and survival of the eosinophils. Moreover,
IgE was also diminished only in the 15d-PGJ2-treated animals in
part due to B-cell inhibition. It has been demonstrated that human
eosinophils express PPAR-c, and stimulation of eosinophils with a
synthetic PPAR-c agonist inhibit the factor-induced eosinophil
activation, such as degranulation, survival, and chemotaxis
[12,13]. Furthermore, administration of PPAR-c agonists had bene-
ﬁcial effects on pathological conditions, including airway hyperre-
sponsiveness and lung eosinophilia in a murine model of asthma
[14] as well as negatively regulates allergic rhinitis in mice [15].
Thus, pharmacological PPAR-c agonists may be a new therapeutic
modality for the treatment of allergic diseases including asthma by
negatively modulating eosinophil functions [24].
In the present study we demonstrated that PPAR-c agonists
15d-PGJ2 and rosiglitazone are able to reduce the eosinophil inﬂux
after the OVA-challenge and this effect is in part due to the de-
crease of eosinopoiesis and the inhibition of some important cyto-
kines involved in this process. Furthermore, there is few data
regarding the potential use of the natural agonist 15d-PGJ2 in the
allergic (asthma-like) model, herein, we demonstrated their
important and potent effect. The 15d-PGJ2 dose used in this study
may be considered somehow high, however, it has been estimated
that >50% of the 15d-PGJ2 added exogenously to a biological sys-
tem binds to albumin which limits its action but also did not in-
duce any known side effect [25].
PPAR-c is also expressed in smooth muscle cells, myoﬁbro-
blasts, endothelial cells of the pulmonary vasculature, and inﬂam-
matory cells such as alveolar macrophages, neutrophils,
eosinophils, lymphocytes, and mast cells [10,26]. Interestingly,
PPAR-c expression is increased in bronchial submucosa, airway
epithelium, and smooth muscle cells of asthmatics when compared
with healthy subjects [27] as well as is involved in airway inﬂam-
mation and remodeling in asthma [28,29]. Thus, the up-regulation
of PPAR-c expression in asthma may represents a self-regulatory
mechanism for preventing airway inﬂammatory and remodeling.
In this way, the use of PPAR-c agonist drugs may be an interesting
approach, as reinforced by our results in which both 15d-PGJ2 and
rosiglitazone decreased the eosinophil migration and eosinopoiesis
after OVA-challenge.
Previous studies have shown that activation of PPAR-c reduces
the expression of various cytokines, airway hyperresponsiveness,
and activation of eosinophils, which are increased in asthma, sug-
gesting the therapeutic potential of PPAR-c agonists for asthma
[14]. Upon allergen challenge, naïve CD4+ T cells differentiate into
a prevailing Th2 effectors phenotype, and these cells predomi-
nantly secret interleukin-4 (IL-4), IL-5, and IL-13 promoting the
recruitment of eosinophils, mast cells and lymphocytes, hyperpla-
sia of smooth muscle, and airway hyperresponsiveness, which are
frequently associated with increased serum IgE concentration [30].
As observed in the present study, the production of the Th2 cyto-
kines (IL-5 and IL-33) was reduced in both treated animals (15d-
Fig. 4. Effect of PPAR-c agonists on cytokines release. The OVA-challenge EWI mice were submitted to the treatments with RGZ or 15d-PGJ2. After 48 h of the challenge, the
peritoneal exudates were harvested and the levels of IL-5(A), IL-33(B), IL-17(C) and IL-23(D) were detected through ELISA assay. Data are the mean ± SD and are
representative of 6 mice/group. #P < 0.05 compared with control groups. ⁄P < 0.05 compared with OVA-challenge EWI without treatment.
Fig. 5. IL-17 is essential to eosinophil migration and eosinopoieisis in EWI model.
C57/B6 WT and C57/B6 IL-17/mice submitted to a subcutaneous implant of heat-
coagulated egg white (EWI) were challenged with OVA (10 lg/cavity) 15 days
thereafter. The eosinophils were harvested from the peritoneal cavity (A) or bone-
marrow (B) from OVA-challenged mice treated with different doses of RGZ. The
eosinophils migration (A) to peritoneal cavity or eosinopoiesis on bone-marrow (B)
were determined in the peritoneal exudates 48 h after challenge of C57/B6 WT
(white bars) and C57/B6 IL-17/ (black bars) mice after challenge with OVA or PBS.
#P < 0.05 compared with EWI-PBS challenge WT mice (ﬁrst white bar). Data are the
mean ± SD and are representative of 6 mice/group, and each count was carried out
at least twice, with differences of less than 10%. ⁄P < 0.05 compared with EWI-OVA-
challenge WT mice.
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indispensable to long-term eosinophilia, as it is the major factor
inducing eosinophil differentiation from lineage-committed pre-
cursors. Furthermore, IL-5 extends the lifespan of inﬁltrating eosin-
ophils and further activates or enhances their effector capabilities
[31].Moreover, the discovery of IL-33 as the ligand for the orphan
Th2 associated receptor ST2 has opened an assortment of different
directions for this pathway, once the IL-33/ST2 axis is thought to be
intimately involved in the promotion and maintenance of allergic
inﬂammation [32]. It has been proposed that IL-33 is released by
damaged cells undergoing necrotic cell death in the presence of
pathogens or allergens, suggesting it may function as an endoge-
nous danger signal or ‘alarmin’ which may propagate the exacerba-
tions of asthma disease [33]. Also, IL-33 promotes secretion of IL-5
and IL-13 from Th2 cells which will stimulate the eosinophil com-
mitment [34]. Thus, the ability to reduce this cytokine is a very
useful drug to control a Th2-disease.
On the other hand, in our system, we have detected the pro-
inﬂammatory cytokine IL-23 which is linked with Th17 cell re-
sponses, through expansion and/or maintenance of the Th17 cells
[35]. IL-17 a cytokine mainly released by Th17 cells, is very impor-
tant for an array of inﬂammatory disease. Previous report demon-
strated that eosinophils are a potential source of IL-17 within
asthmatic airways, suggest that IL-17 might have the potential to
amplify inﬂammatory responses [36]. Both IL-17 and IL-23 were
reduced in animals treated with PPAR-c agonists and consistent
with it, the IL-17 knockout mice did not recruit an important num-
ber of eosinophils after OVA-challenge. In addition, it was demon-
strated the importance of IL-23/IL-23R signaling in the
development of allergic airway inﬂammation by acting on Th2 cells
differentiation [21]. The neutralization of IL-23 decreased antigen-
induced eosinophil recruitment and Th2 cytokine production in
the airways of sensitized mice upon antigen inhalation [20].
Finally we have observed that only 15d-PGJ2 at 1000 lg/kg was
able to decrease the IgE in the serum. Previously it was suggested
that IL-17 may contribute to allergic airway inﬂammation through
Fig. 6. 15d-PGJ2 decrease IgE level and inhibits LPS-induced B cell proliferation. In (A), the OVA-challenge EWI mice were submitted to the treatments with RGZ or 15d-PGJ2,
in different doses. After 48 h of the challenge, blood was drawn by puncturing the orbital plexus and centrifuged. Serum was used for IgE measurements by ELISA. #P < 0.05
compared with control groups. ⁄P < 0.05 compared with OVA-challenge EWI without treatment. Data are the mean ± SD and are representative of 6 mice/group. In (B), spleen
cells (1  106 cells/ml) were pre-incubated with 5 lM of 15-PGJ2 for 1 h and then stimulated with LPS (500 ng/ml) for 24 h. B cells were determined by CD19 positivity by
ﬂow citometry using speciﬁc antibody. Data are the mean ± SD and are representative of one single experiment made in triplicate. #P < 0.05 compared with medium alone.
⁄P < 0.05 compared with LPS stimuli.
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mune responses, and altering the levels of allergen-speciﬁc anti-
body such as IgE [11]. Furthermore, it was demonstrated that
15d-PGJ2 is capable of decrease the expression of FceRI thus avoid-
ing the IgE binding to the cells which in turn decreases the release
of some important mediators to activate the allergic inﬂammation
[37]. Moreover, previous report showed that 15d-PGJ2 inhibit the
IgE-switch in the B cell by suppressing the STAT-6 phosphorylation
[38].
5. Conclusion
In conclusion, the results presented here indicate that PPAR-c
agonists, mainly 15d-PGJ2, reduce eosinophil inﬁltration after
OVA-challenge by decreasing the levels of main Th2 cytokines
(IL-5 and IL-33) as well as IL-23 and IL-17 cytokines, which in turn
decrease the amount of IgE. Our data support the idea that PPAR-c
activation could be a therapeutic strategy for eosinophil-mediated
disorders.
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